Trial Search Results

Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C

The response rate to interferon-based anti-viral therapy for chronic hepatitis C is lower in patients who are obese. However, it is not clear whether this is related to suboptimal dosing of the medication or alterated response in obese patients. Alterated immune response had been reported in obese patients. The goal of current study is to determine the immune response to interferon in obese compared to non-obese chronic hepatitis C in an tissue culture system.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Palo Alto Veterans Institute for Research

Collaborator: Hoffmann-La Roche

Stanford Investigator(s):

Eligibility


Inclusion Criteria:

   - obese (weight > 85kg and BMI>30) or non-obese patients (<75kg and BMI <25) with
   chronic Hepatitis C

   - Chronic Hepatitis C infection with documented HCV RNA

   - Body habitat either as obese or non-obese as defined above

   - Currently not under IFN therapy

   - Non-African American

Exclusion Criteria:

   - Body habitat neither obese or non-obese as defined for the purpose of this study

   - Unable to give consent

   - On immunomodulatory agents such as prednisone

   - Active infection other than Hepatitis C

   - Co-infection with HBV or HIV

   - Active or excessive alcohol use

   - Other cause of chronic Hepatitis

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting